150 related articles for article (PubMed ID: 37929312)
1. Performance of GALAD score and serum biomarkers for detecting NAFLD-related HCC: a systematic review and network meta-analysis.
Li H; Liu H; Yan LJ; Ding ZN; Zhang X; Pan GQ; Han CL; Tian BW; Tan SY; Dong ZR; Wang DX; Yan YC; Li T
Expert Rev Gastroenterol Hepatol; 2023; 17(11):1159-1167. PubMed ID: 37929312
[TBL] [Abstract][Full Text] [Related]
2. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.
Best J; Bechmann LP; Sowa JP; Sydor S; Dechêne A; Pflanz K; Bedreli S; Schotten C; Geier A; Berg T; Fischer J; Vogel A; Bantel H; Weinmann A; Schattenberg JM; Huber Y; Wege H; von Felden J; Schulze K; Bettinger D; Thimme R; Sinner F; Schütte K; Weiss KH; Toyoda H; Yasuda S; Kumada T; Berhane S; Wichert M; Heider D; Gerken G; Johnson P; Canbay A
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):728-735.e4. PubMed ID: 31712073
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis.
Hu B; Tian X; Sun J; Meng X
Int J Mol Sci; 2013 Dec; 14(12):23559-80. PubMed ID: 24317431
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic performances of GALAD score in staging and 1-year mortality of hepatocellular carcinoma: A prospective study.
Jitpraphawan O; Ruamtawee W; Treewatchareekorn M; Sethasine S
World J Gastroenterol; 2024 May; 30(17):2343-2353. PubMed ID: 38813057
[TBL] [Abstract][Full Text] [Related]
5. The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States.
Tayob N; Kanwal F; Alsarraj A; Hernaez R; El-Serag HB
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):415-423.e4. PubMed ID: 35124267
[TBL] [Abstract][Full Text] [Related]
6. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: A multicenter analysis.
Guan MC; Ouyang W; Liu SY; Sun LY; Chen WY; Tong XM; Zhu H; Yang T
Hepatobiliary Pancreat Dis Int; 2022 Dec; 21(6):559-568. PubMed ID: 35643910
[TBL] [Abstract][Full Text] [Related]
7. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma.
Best J; Bilgi H; Heider D; Schotten C; Manka P; Bedreli S; Gorray M; Ertle J; van Grunsven LA; Dechêne A
Z Gastroenterol; 2016 Dec; 54(12):1296-1305. PubMed ID: 27936479
[No Abstract] [Full Text] [Related]
8. Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis.
Wang X; Zhang Y; Yang N; He H; Tao X; Kou C; Jiang J
Biomed Res Int; 2020; 2020():5087643. PubMed ID: 33015170
[TBL] [Abstract][Full Text] [Related]
9. Chinese expert consensus statement on the clinical application of AFP/AFP-L3%/DCP using GALAD and GALAD-like algorithm in HCC.
Huang C; Xiao X; Zhou L; Chen F; Wang J; Hu X; Gao C;
J Clin Lab Anal; 2023 Dec; 37(23-24):e24990. PubMed ID: 38063322
[TBL] [Abstract][Full Text] [Related]
10. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.
Marrero JA; Feng Z; Wang Y; Nguyen MH; Befeler AS; Roberts LR; Reddy KR; Harnois D; Llovet JM; Normolle D; Dalhgren J; Chia D; Lok AS; Wagner PD; Srivastava S; Schwartz M
Gastroenterology; 2009 Jul; 137(1):110-8. PubMed ID: 19362088
[TBL] [Abstract][Full Text] [Related]
11. Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) based on gender, age, multitarget circulating tumour DNA methylation signature and commonly used serological biomarkers for early detection of hepatocellular carcinoma: a multicentre, prospective observational study protocol.
Yang T; Wang N; Wang F; Liu H; Shen F; Lv G
BMJ Open; 2023 Sep; 13(9):e076467. PubMed ID: 37723113
[TBL] [Abstract][Full Text] [Related]
12. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis.
Singal AG; Tayob N; Mehta A; Marrero JA; El-Serag H; Jin Q; Saenz de Viteri C; Fobar A; Parikh ND
Hepatology; 2022 Mar; 75(3):541-549. PubMed ID: 34618932
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.
Ji J; Wang H; Li Y; Zheng L; Yin Y; Zou Z; Zhou F; Zhou W; Shen F; Gao C
PLoS One; 2016; 11(4):e0153227. PubMed ID: 27070780
[TBL] [Abstract][Full Text] [Related]
14. Utility of serological tumor biomarkers for surveillance of hepatocellular carcinoma in patients undergoing dialysis.
Toyoda H; Kikuchi K; Tsuruta Y; Hiraoka A; Tsuji K; Tanaka J
Nephrol Dial Transplant; 2021 May; 36(6):1097-1103. PubMed ID: 33009910
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2002 Jul; 17(7):772-8. PubMed ID: 12121507
[TBL] [Abstract][Full Text] [Related]
16. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.
Ertle JM; Heider D; Wichert M; Keller B; Kueper R; Hilgard P; Gerken G; Schlaak JF
Digestion; 2013; 87(2):121-31. PubMed ID: 23406785
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol.
Huang TS; Shyu YC; Turner R; Chen HY; Chen PJ
Syst Rev; 2013 Jun; 2():37. PubMed ID: 23738605
[TBL] [Abstract][Full Text] [Related]
18. Validation and optimization of AFP-based biomarker panels for early HCC detection in Latin America and Europe.
Beudeker BJB; Fu S; Balderramo D; Mattos AZ; Carrera E; Diaz J; Prieto J; Banales J; Vogel A; Arrese M; Oliveira J; Groothuismink ZMA; van Oord G; Hansen BE; de Man RA; Debes JD; Boonstra A
Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37708457
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early-Stage Hepatocellular Carcinoma.
Choi J; Kim GA; Han S; Lee W; Chun S; Lim YS
Hepatology; 2019 May; 69(5):1983-1994. PubMed ID: 30153338
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3.
Volk ML; Hernandez JC; Su GL; Lok AS; Marrero JA
Cancer Biomark; 2007; 3(2):79-87. PubMed ID: 17522429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
